| Literature DB >> 31830942 |
Ya-Ni Zhang1, Yuan-Yuan Gao1, Si-Da Yang1, Bin-Bin Cao1, Ke-Lu Zheng1, Ping Wei1, Lian-Feng Chen1, Wen-Xiong Chen2.
Abstract
BACKGROUND: X-linked agammaglobulinaemia (XLA) is a rare inherited primary immunodeficiency disease characterized by the B cell developmental defect, caused by mutations in the gene coding for Bruton's tyrosine kinase (BTK), which may cause serious recurrent infections. The diagnosis of XLA is sometimes challenging because a few number of patients have higher levels of serum immunoglobulins than expected. In this study, we reported an atypical case with recurrent meningitis, delayed diagnosis with XLA by genetic analysis at the second episode of meningitis at the age of 8 years. CASE REPORT: An 8-year-old Chinese boy presented with fever, dizziness and recurrent vomiting for 3 days. The cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI) results were suggestive of bacterial meningoencephalitis, despite the negative gram staining and cultures of the CSF. The patient was treated with broad-spectrum antibiotics and responded well to the treatment. He had history of another episode of acute pneumococci meningitis 4 years before. The respective level of Immunoglobulin G (IgG), Immunoglobulin A (IgA) and Immunoglobulin M (IgM) was 4.85 g/L, 0.93 g/L and 0.1 g/L at 1st episode, whereas 1.9 g/L, 0.27 g/L and 0 g/L at second episode. The B lymphocytes were 0.21 and 0.06% of peripheral blood lymphocytes at first and second episode respectively. Sequencing of the BTK coding regions showed that the patient had a point mutation in the intron 14, hemizyous c.1349 + 5G > A, while his mother had a heterozygous mutation. It was a splice site mutation predicted to lead to exon skipping and cause a truncated BTK protein.Entities:
Keywords: Bruton’s tyrosine kinase; Children; Meningitis; Recurrent; X-linked agammaglobulinemia
Mesh:
Substances:
Year: 2019 PMID: 31830942 PMCID: PMC6907138 DOI: 10.1186/s12883-019-1536-7
Source DB: PubMed Journal: BMC Neurol ISSN: 1471-2377 Impact factor: 2.474
Immune parameters of two episodes of intracranial infection
| Immune parameters | 1st episode(4y) | 2nd episode(8y)(after IVIG treatment) |
|---|---|---|
| Leukocytes (109/L) | 22.0↑ | 40.9↑ |
| Neutrophils (109/L /%) | 21.28↑/92 | 36.81↑/90↑ |
| Lymphocytes (109/L /%) | 0.36↓/2↓ | 0.82↓/2↓ |
| Monocytes (109/L /%) | 0.34/2 | 1.64↑/4 |
| CD45+ cells (cells/μL (normal range)) | 2116.82 (1661–6643) | 931.18 (1661–6643) |
| CD3+ cells (cells/μL (normal range))/% | 2079.84 (805–4459)/98.23↑ | 857.19 (805–4459)/92.05↑ |
| CD19 + cells (cells/μL (normal range))/% | 4.46↓(240–1317)/0.21↓ | 0.58↓(240–1317)/0.06↓ |
| NK cells (cells/μL (normal range))/% | 33.02↓(210–1514)/1.56↓ | 73.42↓(210–1514)/7.88↓ |
| IgG (g/L (normal range)) | 4.85↓(5.0–10.6) | 7.42 (6.36–14.04) |
| IgA (g/L (normal range)) | 0.93 (0.34–1.38) | 0.33↓(0.63–1.79) |
| IgM (g/L (normal range)) | 0.1↓(0.44–1.44) | 0.06↓(0.29–1.41) |
| IgE (IU/ML (normal range)) | 49 (0–60) | 33 (0–60) |
| C3 (g/L (normal range)) | 1.75↑(0.8–1.5) | 0.87 (0.8–1.5) |
| C4 (g/L (normal range)) | 0.45↑(0.125–0.425) | 0.24 (0.125–0.425) |
Total T, B, and NK lymphocyte are represented with CD45+ cells, CD3+ cells and CD19 + cells respectively. Values below/above reference ranges are shown with an arrow(↓/↑)
Fig. 1Brain MRI during the two episodes of intracranial infection. A: FLAIR image revealed a little subdural effusion of left frontal, parietal-temporal areas and right frontal area. (1st episode). B: T2-weighted MRI image showedhigh-signal intensity in thickened mucosa of bilateralmaxillary sinus and mastoid process. (1st episode). C: FLAIR image showed high signal on right putamen. (2nd episode). D: Contrast enhanced T1-weighted imagesshowedenhancement of right putamen lesion and bilateral frontal and left temporal lobar meninge. (2nd episode). E: T2-weighted MRI image showedhigh-signal intensity in thickened mucosa of bilateral lethmoidal sinus. (2nd episode)
Fig. 2Direct sequence analysis of blood samples from the patient and his parents with reverse sequence